Atopic Dermatitis-Japan Drug Forecast and Market Analysis to 2024 is a new market research publication announced by Reportstack. Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit.
By the mid-to-late term of the report 2014 to 2024 forecast, Sanofi/Regeneron’s dupilumab is expected to reshape the adult moderate and severe treatment landscape and to slowly enter the market for younger patients with milder forms of the disease.
Complete report available @ Atopic Dermatitis-Japan Drug Forecast and Market Analysis to 2024
Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in the US.
This report values the atopic dermatitis market in Japan at $397.0m in 2014. Growth within that market will stem from the positive uptake of systemic agents and the pipeline therapy dupilumab. In terms of branded products, Protopic dominates the topical calcineurin inhibitor class in Japan with estimated sales of $31.5m in 2014. Since its key competitor Elidel is not available in Japan, Protopic’s strong stance in that market remains relatively unchallenged throughout the 10-year forecast.
Scope
- Overview of Atopic Dermatitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Japan including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.
- Detailed information on the key drugs in Japan including product Atopic Dermatitiscription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Japan from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting Japan Atopic Dermatitis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in Japan.
- Stay ahead of the competition by understanding the changing competitive landscape for Atopic Dermatitis.
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2014-2024 in Japan.
Contact:
Debora White
Manager - Marketing
Ph: +1-888-789-6604
Reportstack Market Research
###
No comments:
Post a Comment